Last updated: September 9, 2026
Formoterol fumarate/mometasone furoate is a mature inhaled corticosteroid/long-acting beta2-agonist combination marketed in the United States as Dulera by Merck. The product has durable asthma demand but limited growth, no COPD indication in the United States, declining differentiation against generic and branded alternatives, and increasing exposure to generic inhaler competition. Merck does not separately disclose Dulera revenue in recent annual reports, indicating that the product is no longer a material standalone driver of group financial performance. [1][2]
What is formoterol fumarate/mometasone furoate?
Formoterol fumarate/mometasone furoate combines:
| Component |
Pharmacologic role |
Commercial relevance |
| Mometasone furoate |
Inhaled corticosteroid |
Suppresses airway inflammation |
| Formoterol fumarate |
Long-acting beta2-agonist |
Provides sustained bronchodilation |
| Dosage form |
Metered-dose inhalation aerosol |
Requires inhaler manufacturing, dose uniformity and device compatibility |
| U.S. brand |
Dulera |
Merck product |
| U.S. indication |
Maintenance treatment of asthma |
Not approved for acute bronchospasm or U.S. COPD treatment |
| U.S. strengths |
50/5, 100/5 and 200/5 mcg per actuation |
Mometasone/formoterol dose combinations |
The FDA approved Dulera in 2010 for twice-daily maintenance treatment of asthma in patients aged 12 years and older. The FDA later expanded use to children aged 5 to 11 years with the lower-strength formulation. Dulera is not a rescue inhaler and must not be used for acute bronchospasm. [3]
Mometasone furoate/formoterol is clinically positioned against other ICS/LABA products, including budesonide/formoterol, fluticasone propionate/salmeterol and fluticasone furoate/vilanterol.
How large is the market for mometasone/formoterol?
The addressable market is the maintenance asthma segment rather than the entire respiratory drug market. Demand is supported by the chronic nature of asthma, guideline-based use of inhaled corticosteroids and the need for combination therapy in patients inadequately controlled on corticosteroid monotherapy.
The product faces four structural constraints:
- The U.S. indication is asthma only.
- It lacks the COPD label held by several competing ICS/LABA products.
- Multiple generic and authorized-generic alternatives compete for formulary placement.
- Pharmacy benefit managers increasingly prefer lower-net-cost inhalers.
The most important commercial competitors include:
| Product |
Active ingredients |
Main commercial position |
| Dulera |
Mometasone/formoterol |
Asthma maintenance |
| Symbicort |
Budesonide/formoterol |
Asthma and COPD; widely established |
| Advair and authorized generics |
Fluticasone propionate/salmeterol |
Asthma and COPD |
| Breo Ellipta |
Fluticasone furoate/vilanterol |
Once-daily asthma and COPD treatment |
| AirDuo and generic equivalents |
Fluticasone propionate/salmeterol |
Lower-cost asthma alternative |
| Generic budesonide/formoterol |
Budesonide/formoterol |
Major price competitor in the United States |
Budesonide/formoterol has a significant strategic advantage because of its established role in both asthma and COPD and because generic versions have expanded access. Fluticasone/salmeterol also has a large installed base and substantial generic availability.
What is the financial trajectory of Dulera?
Dulera’s financial trajectory is consistent with a late-life branded respiratory product: initial uptake after approval, a period of established use, and subsequent erosion from formulary pressure and generic competition.
Merck’s public reporting does not provide a separate current revenue line for Dulera. The product is included within broader pharmaceutical or respiratory product categories, preventing a precise standalone revenue calculation from the company’s latest filings. [1][2]
| Financial factor |
Effect on Dulera |
| Mature U.S. asthma market |
Limits unit growth |
| Generic ICS/LABA competition |
Reduces price and market share |
| Net-price rebates |
Compresses realized revenue |
| Pediatric indication |
Supports volume but does not materially change market structure |
| Limited geographic disclosure |
Makes global product-level revenue difficult to quantify |
| Merck portfolio concentration |
Makes Dulera financially immaterial relative to Keytruda and other major products |
The primary financial risk is not a sudden loss of demand. Asthma patients require long-term maintenance therapy, and inhaler switching can be constrained by device familiarity and physician preference. The larger risk is gradual net-price erosion as payers place lower-cost alternatives on preferred formularies.
Dulera therefore remains commercially relevant at the product level but is unlikely to have a meaningful effect on Merck’s consolidated growth, earnings trajectory or valuation.
When does Dulera lose exclusivity?
Dulera’s principal market exclusivity has already expired. FDA regulatory exclusivity is separate from patent protection and is not the main remaining barrier to generic competition.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| U.S. regulatory exclusivity |
No longer a meaningful commercial barrier |
| Active-ingredient patents |
Mature or expired relative to launch period |
| Combination and formulation patents |
Historically provided the more relevant protection |
| Device and manufacturing know-how |
May continue to affect generic development and launch timing |
The commercial question is therefore whether generic applicants can satisfy the FDA’s requirements for a complex inhalation product. Inhaled combinations are more difficult to copy than conventional oral tablets because applicants must demonstrate pharmaceutical equivalence, device performance, aerodynamic particle size distribution, delivered dose uniformity and, where applicable, comparative bioequivalence.
Patent expiry alone does not guarantee immediate generic substitution. Product-specific device testing, formulation development, manufacturing scale-up and state substitution rules determine the timing of actual market penetration.
What patents protect formoterol fumarate/mometasone furoate?
Protection for Dulera has historically involved several layers:
Active ingredients
Mometasone furoate and formoterol fumarate are old pharmaceutical compounds. Their original compound patents do not provide meaningful long-term exclusivity for Dulera.
Combination formulation
The more important protection involved compositions combining mometasone furoate and formoterol fumarate in an inhaled product. These patents addressed variables such as:
- The corticosteroid-to-bronchodilator combination
- Particle size and micronization
- Suspension formulation
- Propellant systems
- Excipient selection
- Chemical and physical stability
- Delivered-dose consistency
Inhaler and manufacturing technology
Additional barriers can arise from:
- Metered-dose inhaler valve design
- Canister and actuator compatibility
- Homogeneous suspension formation
- Filling and crimping processes
- Control of aggregation and settling
- Manufacturing specifications for aerodynamic performance
The enforceable patent position must be determined from the FDA Orange Book and the relevant patent registers at the time of a specific generic filing. Orange Book listings can change through delisting, expiration, terminal disclaimers, patent-term adjustments and litigation outcomes. The principal commercial conclusion is that formulation and device-related protection has been more relevant than the original patents covering either active ingredient.
Are there Paragraph IV challenges to Dulera?
Generic applicants may challenge listed Dulera patents through an abbreviated new drug application containing a Paragraph IV certification. That certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.
A Paragraph IV filing can trigger litigation under the Hatch-Waxman Act. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and litigation developments. [4]
For Dulera, the practical significance of any Paragraph IV dispute depends on:
- Which Orange Book patents remain listed
- Whether the generic applicant challenges all relevant patents
- Whether the applicant seeks approval for all strengths
- Whether the patent holder asserts formulation, device or manufacturing claims
- Whether the parties settle before trial
- Whether a court grants a preliminary injunction or finds infringement
The existence of an ANDA or Paragraph IV certification does not establish that a generic will launch. Inhaler litigation often produces staggered launches by strength, authorized generic arrangements or settlements with dates earlier than the ultimate patent expiration.
What is the Orange Book status of Dulera?
Dulera is an FDA-approved prescription drug listed in the Orange Book under its new drug application. The relevant Orange Book analysis must distinguish between:
- The reference listed drug, Dulera.
- Listed patents covering the drug, formulation or use.
- Generic ANDAs referencing Dulera.
- Therapeutic-equivalence ratings.
- Patent certifications and litigation status.
The Orange Book does not provide a complete analysis of every commercial barrier. It generally does not capture all manufacturing know-how, device engineering, trade secrets or non-listed process patents. Those factors can delay generic commercialization even after listed patent barriers have weakened. [5]
What generic entry risks exist?
Generic entry risk is high in the long term and moderate in the near term for a specific branded presentation.
High long-term risk
The product has mature active ingredients, expired regulatory exclusivity and a well-defined reference product. Those characteristics support eventual generic competition.
Moderate near-term risk
The formulation is a pressurized inhalation aerosol containing two active ingredients. Generic development requires specialized analytical and manufacturing capabilities. The market may therefore experience a slower ramp than a conventional oral generic.
Commercial substitution risk
Once a therapeutically equivalent generic receives approval, substitution may be limited by:
- Formulary tiering
- State pharmacy-substitution rules
- Device differences
- Physician prescribing patterns
- Patient ability to use the new inhaler
- Contracts between manufacturers and pharmacy benefit managers
An authorized generic could accelerate net-price erosion while preserving some supply-chain control for the brand owner or its commercial partner.
How does Dulera compare with Symbicort and Advair?
| Attribute |
Dulera |
Symbicort |
Advair |
| ICS component |
Mometasone |
Budesonide |
Fluticasone propionate |
| LABA component |
Formoterol |
Formoterol |
Salmeterol |
| Asthma indication |
Yes |
Yes |
Yes |
| COPD indication in U.S. |
No |
Yes |
Yes |
| Generic competition |
Increasing |
Established |
Extensive |
| Device familiarity |
Moderate |
High |
High |
| Strategic advantage |
Asthma-focused combination |
Asthma and COPD, broad clinical use |
Large installed base and low-cost options |
| Growth outlook |
Mature to declining |
Larger competitive base |
Mature with generic pressure |
Dulera’s formoterol component gives it a faster-onset LABA profile than salmeterol-containing products. That pharmacologic distinction has clinical relevance, but it has not created a durable commercial moat because budesonide/formoterol offers a similar LABA component and has broader market penetration.
Which companies are challenging the market?
The competitive field includes branded multinational manufacturers, generic respiratory specialists and inhaler-device suppliers.
Key competitive groups include:
- AstraZeneca, through Symbicort and other respiratory products
- GlaxoSmithKline, through Advair and related inhaled therapies
- Teva, through respiratory generics and branded inhalers
- Viatris, through generic and inhaled respiratory products
- Cipla, Lupin and other companies developing complex inhaled generics
- Device and contract-manufacturing specialists supplying metered-dose inhaler components
Competition is increasingly based on net price, payer access, device usability and supply reliability rather than on molecule-level differentiation.
What manufacturing and intellectual-property barriers remain?
The main barrier is technical execution. A manufacturer must produce a stable suspension with reproducible dose delivery across the product’s shelf life. Small changes in particle size, propellant composition, actuator geometry or valve performance can alter lung deposition and delivered dose.
Relevant manufacturing risks include:
- Particle agglomeration
- Dose-content uniformity
- Canister and valve compatibility
- Propellant impurities
- Moisture control
- Actuator reproducibility
- Batch-to-batch aerodynamic performance
- Scale-up from development to commercial production
These issues can support intellectual-property claims even when broad composition claims have expired. They also raise the cost and duration of abbreviated approval programs.
What is the likely generic launch scenario?
The most likely scenario is staged generic entry rather than immediate complete displacement.
Scenario 1: Limited early entry
One or more approved generics enter with restricted strength availability or limited payer coverage. The branded product retains a meaningful share through device loyalty and contracting.
Scenario 2: Broad generic competition
Several suppliers enter after regulatory and patent barriers fall. Net prices decline rapidly, and Dulera volume migrates to lower-cost equivalents.
Scenario 3: Authorized-generic defense
Merck or a commercial partner supplies an authorized generic. This can preserve some volume and improve price control but usually accelerates category-level price compression.
The highest-probability outcome is a gradual decline in branded revenue, followed by a sharper reduction once multiple equivalent inhalers receive preferred formulary status.
What licensing deals affect the product?
No major recent transaction has transformed the commercial outlook for Dulera. Its value is primarily tied to Merck’s existing respiratory portfolio, manufacturing infrastructure and commercial contracts rather than to a new licensing platform.
Any future licensing or supply arrangement would likely concern:
- Regional commercialization
- Generic or authorized-generic supply
- Inhaler manufacturing
- Device technology
- Portfolio divestiture
- Product rights in markets where Merck has reduced commercial presence
The asset’s mature lifecycle makes an outright high-value licensing transaction less likely than a regional rights transfer or supply agreement.
What patent litigation and settlements affect Dulera?
Patent litigation risk is concentrated in the period between ANDA filing and commercial launch. A settlement could establish:
- An agreed generic entry date
- A license to listed patents
- A supply arrangement
- An authorized-generic structure
- Restrictions on launch strength or formulation
The absence of a widely reported current blockbuster-scale Dulera dispute does not remove litigation risk. The relevant status depends on each ANDA applicant and the particular Orange Book patent claims challenged. Hatch-Waxman case filings and FDA approval records should be reviewed together because court outcomes alone do not establish commercial launch timing.
What is the investment and revenue exposure?
Dulera has low strategic importance to Merck relative to its oncology, immunology and vaccine franchises. Product-level exposure remains relevant for:
- Respiratory portfolio valuation
- Generic-entry forecasting
- Contract manufacturing
- Inhaler supply-chain assets
- Licensing and divestiture analysis
- Competitive positioning in asthma
The product is unlikely to be a material earnings catalyst. The more relevant financial question is the pace of revenue erosion and the cost of maintaining manufacturing and commercial infrastructure for a mature inhaled product.
Key Takeaways
- Formoterol fumarate/mometasone furoate is marketed in the United States as Dulera.
- The product is approved for asthma maintenance, not U.S. COPD treatment.
- Regulatory exclusivity has expired, and the principal historical protection came from combination, formulation, device and manufacturing patents.
- Generic-entry risk is high over the long term but can be delayed by inhaler-development complexity.
- Merck does not separately disclose current Dulera revenue, limiting precise product-level financial modeling.
- Dulera is commercially mature and unlikely to materially affect Merck’s consolidated growth.
- Symbicort and Advair have stronger market positions because of broader COPD exposure, established physician use and extensive generic competition.
- The likely outcome is progressive net-price erosion, with the speed determined by approved generic suppliers, patent settlements and payer substitution.
FAQs
Is Dulera the same as formoterol fumarate/mometasone furoate?
Yes. Dulera is the U.S. brand name for an inhaled combination of mometasone furoate and formoterol fumarate.
Is there a generic version of Dulera?
Generic development and approval depend on the individual manufacturer, strength and FDA approval status. A generic product must demonstrate equivalence to the Dulera reference inhaler and satisfy applicable patent-certification requirements.
Can Dulera be used for COPD?
Dulera is approved in the United States for asthma maintenance. It is not approved by the FDA for COPD treatment.
Does Dulera contain a rescue bronchodilator?
No. Dulera is a maintenance inhaler. Acute bronchospasm requires a separate short-acting rescue medication prescribed for that purpose.
Why are generic Dulera inhalers harder to develop than generic tablets?
Generic inhalers must match formulation performance, aerosol particle distribution, delivered dose, device operation and manufacturing consistency. These requirements create technical barriers beyond the active ingredients themselves.
References
- Merck & Co., Inc. (2024). 2023 annual report.
- Merck & Co., Inc. (2023). 2022 annual report.
- U.S. Food and Drug Administration. (2023). Dulera prescribing information.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application and Paragraph IV certification guidance.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
